Ask the Experts: Existing and Novel Therapeutics in the Management of Recurrent Clostridioides difficile Infection

This 1-hour interprofessional educational activity examines recent data on Clostridioides difficile infection (CDI) and uses a case-based approach to apply recommendations to the management of recurrent CDI (rCDI). CDI is one of the most common healthcare-associated infections and the most common cause of mortality in patients with gastroenteritis in the United States. rCDI has been shown to be associated with increased morbidity, mortality, and healthcare costs, as well as having a negative impact on the patient’s quality of life. Recent updates to guidelines have resulted in practitioners having varying treatment and management options for CDI. This webinar will review the pathogenesis of CDI that can lead to rCDI episodes and explore the role of current and emerging therapeutics in the interprofessional management of rCDI.


Thursday, Mar. 23
1 - 2 p.m. ET

Speakers

Anne Gonzales-LunaAnne Gonzales-Luna PharmD, BCIDP
Activity Chair
Research Assistant Professor - Infectious Diseases
University of Houston College of Pharmacy
Houston, Texas

Andrew SkinnerAndrew Skinner MD
Assistant Professor of Medicine
Loyola University Medical Center
Staff Physician and Research
Edward Hines Jr., VA Hospital
Maywood, Illinois

Target Audience

This activity was planned to meet the educational needs of pharmacists, physicians, and other healthcare providers who care for patients with Clostridioides difficile infection.

Learning Objectives

  • Analyze the pathogenesis of recurrent Clostridioides difficile infection (rCDI).
  • Evaluate current and emerging therapies for the prevention of rCDI.
  • Recommend evidence-based strategies for the use of emerging therapies in the interprofessional management of rCDI.

Agenda

  • 1:00 pm - Welcome and Introductions
     Anne Gonzales-Luna, PharmD, BCIDP and Andrew Skinner, MD
  • 1:05 pm - Ask the Experts: Existing and Novel Therapeutics in the Management of Recurrent Clostridioides difficile Infection
     Andrew Skinner, MD, Anne Gonzales-Luna, PharmD, BCIDP
  • 1:50 pm - Questions and Answers
     Andrew Skinner, MD, Anne Gonzales-Luna, PharmD, BCIDP

Accredited for CPE and CME

ACPE #:0204-0000-23-404-L01-P
CE Credit: 1.0 contact hours (0.10 CEUs)
Activity Type: Application-based
Activity Fee: No charge

To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.

 

 

Relevant Financial Disclosures

The following persons in control of this activity’s content have relevant financial relationships:
Andrew Skinner – Paratek Pharmaceuticals, Inc.: Independent Research Grant; Recursion Pharmaceuticals, Inc.: Consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.

ACPE logo black and white

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

 
ACPE logo black and white The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASHP Advantage logo Provided by ASHP. Supported by an educational grant from Merck.
For questions and assistance to participate, contact us.